July 14, 2014 3:19 AM ET

Pharmaceuticals

Company Overview of Ranbaxy Pharmaceuticals, Inc.

Company Overview

Ranbaxy Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets generic, branded, and over the counter pharmaceutical products. It offers anti-infective, cardiovascular, NSAID, anti-expectorant, analgesic, gastrointestinal, CNS, and pharmaceutical substance products for patients and medical professionals. The company’s generic products are manufactured as capsules, tablets, and suspensions. It also offers services in the areas of active pharmaceutical ingredients development and production, dosage form development and manufacturing, contract manufacturing, sales and marketing, marketing strategies, and licensing arrangements. Ranbaxy Pharmaceuticals sells its pro...

600 College Road East

Suite 2100

Princeton, NJ 08540

United States

Founded in 1994

Phone:

609-720-9200

Fax:

609-720-1155

Key Executives for Ranbaxy Pharmaceuticals, Inc.

Chief Executive Officer
Age: 41
Vice President of Finance
Chief Executive Officer of Ramnaxy and Managing Director of Ranbaxy
Age: 59
Vice President of Corporate Communications and Vice President of Government Affairs
Executive Director of Medical and Clinical Affairs
Compensation as of Fiscal Year 2014.

Ranbaxy Pharmaceuticals, Inc. Key Developments

Attorney General Eric T. Schneiderman Announces Settlement with Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc for Entering into Anticompetitive Arrangement

Attorney General Eric T. Schneiderman announced a settlement with two generic pharmaceutical manufacturers, Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., resolving concerns that an agreement between them unlawfully restricted competition. The collusive agreement, under which each of the generic drug companies committed not to challenge certain regulatory exclusivities held by the other, served to protect each party's market positions with respect to dozens of drugs, and reduced the risk that each would face greater competition for its generic drugs. The settlement requires the companies to terminate their unlawful agreement, commit not to enter into similar agreements in the future, and make a monetary payment to the State. The case also represents the latest application of recent legal precedent arising out of challenges to pay for delay agreements between brand name and generic pharmaceutical manufacturers. The agreement between Ranbaxy and Teva relates to a type of regulatory exclusivity awarded to the first manufacturer that seeks to market a generic version of a brand manufacturer's drug prior to expiration of the brand manufacturer's patents.

Ranbaxy Pharmaceuticals, Inc. Enters into an In-Licensing Agreement with Alembic Pharmaceuticals Limited

Ranbaxy Pharmaceuticals Inc. announced that it has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market Desvenlafaxine Base Extended Release Tablets in the U.S. healthcare system. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the New Drug Application (NDA) Desvenlafaxine Base Extended Release Tablets. The product is a bioequivalent version of innovator drug, Pristiq(R) by Pfizer, Inc. The market size for Pristiq(R) is USD 590 million. Desvenlafaxine Base Extended Release Tablets is indicated for the treatment of major depressive disorder. The product will be available in 50 mg and 100 mg dosage strengths. Alembic has received the final approval from the U.S. Food and Drug Administration and Ranbaxy expects the product to be available in the U.S. marketplace during the first quarter of 2013.

Gainey & McKenna Files Lawsuit Against Ranbaxy Pharmaceuticals, Inc. for Recalled Prescription Drug, Atorvastatin

Gainey & McKenna announces that a class action lawsuit has been filed in the United States District Court, District of New Jersey on behalf of a class of all purchasers of certain bottles of Atorvastatin (generic Lipitor) that were manufactured and sold by Ranbaxy Pharmaceuticals, Inc. The pharmaceutical company recently conducted a limited, voluntary recall at the retail level only for Atorvastatin calcium tablets, (generic Lipitor). The recall concerns its 10mg 20mg and 40mg dosage strengths, packaged in 90's and 500 count bottles and only with respect to certain select lot numbers. Ranbaxy admitted that the product contained glass particles. The Complaint alleges that the defendants manufactured and sold a dangerous and defective product, violated consumer fraud laws, and otherwise acted improperly with respect to the tainted Atorvastatin. The class action seeks a total product recall, with notice to consumers about the tainted product. The lawsuit also seeks a refund of the money paid for the product.

Similar Private Companies By Industry

Company Name Region
DaVinci Laboratories of Vermont United States
Allena Pharmaceuticals, Inc. United States
Edison Pharmaceuticals, Inc. United States
Virbac Corporation United States
KI NutriCare, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ranbaxy Pharmaceuticals, Inc., please visit www.ranbaxy.com/us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.